Making the most of a special gift

Committing to be an organ and tissue donor is a generous decision that can save the lives. You may know someone who has given this special gift or that has made the decision to do so in the future.

Today thousands of patients are on the waiting list for an organ. The organ gift from one donor could save the lives of 8 to 10 people and tissue gift could improve the life of hundreds of people.  A Phoenix based company has developed new technologies that could ultimately extend the impact of one donor’s gift to benefit hundreds, thousands or even more.

Humabiologics is a regenerative medicine company founded in 2018 by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers.  The company partners with FDA registered and accredited tissue banks around the US to utilize thoroughly screened donated human tissue that will not be used for transplant.

The supply of high-quality and affordable human-derived biomaterials for translational research is severely limited. Academic and industry regenerative medicine researchers rely on animal-derived alternatives that are often expensive and not clinically or physiologically relevant to human tissues. Animal-derived alternatives can also present regulatory and safety challenges that can slow down the development of new patient therapies.

Humabiologics has solved this problem through their transformative technology that converts donated tissue that is not used for transplant into affordable and high-quality biomaterials for research.

Humabiologics products are used by life science companies and academic researchers to develop innovative therapies that address debilitating diseases and improve the quality of life for patients. The company’s products are used in the field of tissue engineering, regenerative medicine, cell culture, 3D bioprinting disease models, drug toxicity testing, and many other translational therapeutic research applications.

Humabiologics launched the first of its kind human bone gelatin in late 2019 and provides one of the most affordable native human skin collagens for hydrogel applications and 3D bioprinting. It also introduced the world’s first native human collagen and gelatin bioinks for tissue and organ bioprinting. These bioinks are making a difference in research labs across the globe.

Humabiologics successfully raised $1 million in seed funding in 2020 amid the current health emergency and challenging economic times. The company is tripling its manufacturing space in 2021 to meet the increasing demand for its products and created Phoenix-based job opportunities including 4 full time opportunities.

“New and emerging health solutions based on regenerative medical technologies have the potential to greatly improve the human condition,” said Joan Koerber-Walker, president & CEO of the Arizona Bioindustry Association. “Humabiologics is helping researchers and companies accelerate the pace of medical innovation while maximizing the impact of an organ and tissue donor’s very special gift.”

Humabiologics is being honored with a 2021 AZBio Fast Lane Award for the progress they are making in commercializing and delivering products that can help accelerate the pace of medical innovation.

READ MORE